Takeda Pharmaceuticals will focus on announcing advanced tumor pipeline progress and solid tumor pipeline research results at the 2026 European Society of Medical Oncology Conference. The core content is the newly revealed phase III clinical trial data of arcotargotivitecan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.